Watch Ticker

Exelixis Inc

Go to Exelixis Inc Website

$36.65

-0.61 (-1.64%)

Live

Previous Close

$37.26

Day Range

$36.45 - $37.58

Previous Day Range

$35.8801 - $38.09

Market Cap

$10.0 billion USD

Day Vol.

4.2 million

Previous Day Vol.

5.8 million

Currency

USD

Primary Exchange

Nasdaq

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and f...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Ipsen - Approbation de Cabometyx® dans l’UE pour les tumeurs neuroendocrines avancées précédemment traitées

The European Commission approved Cabometyx for treating adult patients with advanced pancreatic and extra-pancreatic neuroendocrine tumors that have progressed after previous systemic treatment, offering a new therapeutic option with demonstrated efficacy in clinical trials.

Related tickers: EXEL, TAK, IPSEY.

Read Full Article

Ipsen - Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors

The European Commission approved Cabometyx for treating adult patients with unresectable or metastatic neuroendocrine tumors who have progressed after prior systemic therapy, offering a new treatment option for patients with limited therapeutic alternatives.

Related tickers: EXEL, TAK, IPSEY.

Read Full Article

Trending Tickers

Please sign in to view